Disclosures:

OVERVIEW OF ACTIVITY

It is important for medical oncologists, hematologists and fellows to be aware of similarities and differences between their patterns of cancer care and those of other community practitioners. In addition, the recognition that heterogeneity exists within the treating oncology community underscores the existence of clinical situations for which the research evidence to support a single definitive approach may be suboptimal.

This program focuses on the self-described practice patterns of randomly selected community medical oncologists and hematologists in a variety of key clinical scenarios in breast cancer. Also included are clinical investigator commentaries describing clinical scenario-related treatment selection and management patterns. This CME program provides medical oncologists, hematologists and hematology-oncology fellows with information on national cancer patterns of care to assist with the development of best-practice clinical management strategies for breast cancer.

LEARNING OBJECTIVES

• Integrate validated genomic assays into the clinical management of ER-positive, node-negative and node-positive early breast cancer.
• Appraise patterns of adjuvant chemotherapy administration of clinical investigators and practicing oncologists, based on age, clinicopathologic characteristics and genomic risk status.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of an interactive text component. To receive credit, the participant should respond to the interactive poll questions, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/POCB112/1/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

William J Gradishar, MD
Betsy Bramsen Professor of Breast Oncology
Professor of Medicine
Director, Maggie Daley Center for Women's Cancer Care
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

No real or apparent conflicts of interest to disclose.

Beth Overmoyer, MD
Assistant Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

No real or apparent conflicts of interest to disclose.

Mark D Pegram, MD
Director, Breast Oncology Program
Co-Director, Experimental Therapeutics Program
Professor of Medicine
Stanford University Medical Center
Stanford, California

Advisory Committee: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consulting Agreement: Genentech BioOncology; Data and Safety Monitoring Board: Pfizer Inc.

Edith A Perez, MD
Deputy Director, Mayo Clinic Cancer Center
Group Vice Chair, Alliance of Clinical Trials in Oncology
Serene M and Frances C Durling Professor of Medicine
Mayo Clinic
Jacksonville, Florida

Paid Research: Genentech BioOncology, GlaxoSmithKline, Sanofi.

George W Sledge Jr, MD
Ballve-Lantero Professor of Oncology
Professor of Medicine and Pathology
Co-Director of the IUSCC Breast Cancer Research Program
Indiana University Simon Cancer Center
Indiana University School of Medicine
Indianapolis, Indiana

No real or apparent conflicts of interest to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology and Genomic Health Inc.

Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: April 2012
Expiration date: April 2013

After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.